Adipotide

Buy Adipotide Online

Adipotide, also known as FTPP or Prohibitin-Targeting Peptide, is a synthetic peptidomimetic investigated for its ability to target the blood vessels supplying white adipose tissue. Research has primarily focused on fat loss, adipose tissue biology, and metabolic effects in animal models.

Product Information

Adipotide combines a prohibitin-targeting sequence with a pro-apoptotic peptide sequence. The design aims to selectively target blood vessels associated with white adipose tissue and trigger apoptosis in the targeted vascular cells. Research has produced notable effects in obese animal models, but human development remains very limited.

How It Works

Adipotide is designed to recognize prohibitin-associated targets on the vasculature of white fat. After binding, its pro-apoptotic component is intended to disrupt mitochondrial function and promote cell death in the targeted vascular tissue.

POTENTIAL BENEFITS

1. Adipose Tissue Research

Animal research has shown that Adipotide can reduce white adipose tissue by targeting its supporting vasculature. This makes it a distinctive model for studying fat-tissue biology.

2. Body-Weight Research

Studies in obese mice and rhesus monkeys reported substantial reductions in body weight following Adipotide exposure. These findings provide the main basis for its continued research interest.

3. Metabolic Research

Preclinical studies have also investigated changes in glucose handling and insulin sensitivity following reductions in adipose tissue. These findings have helped establish Adipotide as a metabolic research compound.

4. Targeted Apoptosis Research

Adipotide represents a targeted approach to apoptosis rather than a conventional appetite-suppressing mechanism. Its design provides a useful research model for studying vascular targeting and selective tissue destruction.

Dosage

There is no established human dose for Adipotide. The frequently cited animal research used approximately 0.5 mg/kg/day in obese rhesus monkeys, while a terminated first-in-human study reportedly used an investigational starting dose of 0.03 mg/kg/day. The human study did not produce a published efficacy or safety dataset, so these figures should not be treated as an established dosing protocol.

Side Effects

Renal toxicity is the most important safety concern reported in preclinical development. Monkey studies identified dose-related kidney effects, which significantly limited translation of the compound toward human use. Human safety and efficacy remain insufficiently established.

References

1. Kolonin MG, et al. Reversal of obesity by targeted ablation of adipose tissue. Nature Medicine. 2004.
2. Barnhart KF et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Science Translational Medicine. 2011.
3. Adipotide/FTPP research identity and published references.

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Please click here to see how purchases actually work on this site.